



**UBS (Lux) Equity SICAV**  
*Société d'Investissement à Capital Variable*  
33 A, avenue J.F. Kennedy  
L-1855 Luxembourg  
RCS Luxembourg Nr. B 56386  
(the "Company")

www.ubs.com

---

**Notice to shareholders of UBS (Lux) Equity SICAV – China Health Care (USD)**  
(the "Sub-Fund")

---

The board of directors of the Company (the "**Board of Directors**") wishes to inform you that, pursuant to the Company's Articles of Incorporation and Sales Prospectus, it has decided to liquidate the Sub-Fund with effect on 16 October 2024 (the "**Liquidation Date**").

The Board of Directors considers that the lower and further decreasing level of assets in the Sub-Fund would not permit economically efficient management of the Sub-Fund to be carried out over the foreseeable future in the best interest of its shareholders.

No new subscription orders for shares of the Sub-Fund have been accepted since the cut-off time on 24 September 2024, and after the cut-off time on 15 October 2024, no more requests to redeem or convert shares of the Sub-Fund will be processed. All of the anticipated liquidation costs have been charged to the Sub-fund from the date of the Board of Director's resolution to liquidate the Sub-fund in order to ensure the fair and equal treatment of the shareholders.

All shares held in any share class of the Sub-Fund as of the close of business on the Liquidation Date will be compulsorily redeemed at the applicable net asset value per share calculated in accordance with the sales prospectus and Company's Articles of Incorporation.

After the liquidation, any remaining portion of the liquidation proceeds that has not been reclaimed by the shareholders will be put in safekeeping with the public depository institution (*Caisse de Consignation*) for those entitled to it.

We wish to inform you that your investment in investment funds may be taxable. Please consult your tax adviser if you have any tax-related questions as a result of this liquidation.

Luxembourg and Basle, 16 October 2024 | The Company

The Prospectus, the PRIIPs KID (Packaged Retail and Insurance-based Investment Products Key Information Document), the Articles of Association and the annual and semi-annual reports relating to the Company may be obtained or ordered free of charge from the Paying Agent in Switzerland, UBS Switzerland AG, Bahnhofstrasse 45, 8001 Zurich and its branches in Switzerland, from the Representative in Switzerland UBS Fund Management (Switzerland) AG and from UBS Infoline (0800 899 899).

The domicile of the Company is Luxembourg.

The Company:  
UBS (Lux) Equity SICAV  
33 A, avenue J.F. Kennedy  
L-1855 Luxembourg

The Representative in Switzerland:  
UBS Fund Management (Switzerland) AG  
Aeschenvorstadt 1  
CH-4051 Basel

24.296\_24.150RS

UBS Fund Management (Switzerland) AG is a member of UBS Group AG.  
© UBS 2024 The key symbol and UBS are among the protected trademarks of UBS. All rights reserved.